Dispatches from Ukraine. Day 1,504.

Dec 10 (Reuters) - A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial treatments, potentially allowing patients to avoid grueling bone marrow transplants, preliminary data from a small mid-stage trial suggest. Patients in the trial had received initial treatments that eliminated nearly all of their cancer cells.

Setting out on a waterway journey is likened to venturing into a moving material of stunning scenes, dynamic societies, and verifiable